Hormonal
ChREBP acts as a central regulator linking carbohydrate intake to metabolic disease; its overexpression causes fatty liver and insulin resistance, while its deletion prevents obesity and fatty liver but may cause other metabolic issues like insulin resistance in adipose tissue.
While high sugar intake drives disease via ChREBP, completely eliminating carbohydrates or targeting this pathway aggressively may have unintended metabolic consequences. A balanced approach focusing on reducing HFCS while maintaining adequate complex carbohydrate intake is likely optimal.
Chrebp overexpression causes fatty liver and lower plasma glucose levels, and ChREBP deletion prevents obesity and fatty liver... adipose-specific Chrebp-knockout mice show insulin resistance.
Why this rating
Based on consistent findings across multiple knockout and overexpression mouse studies cited in the review.
Source
The Roles of Carbohydrate Response Element Binding Protein in the Relationship between Carbohydrate Intake and Diseases
Katsumi Iizuka · International Journal of Molecular Sciences · 2021
DOI 10.3390/ijms222112058
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →